Inhibition of LERK-2-mediated cell adhesion
AssigneeMillennium Pharmaceuticals, Inc.
InventorsMichael J. Briskin, Lily Zou
Life of this patent
Estimating the term…
Abstract
Methods of modulating LERK-2-mediated cell adhesion, as well as methods of modulating angiogenesis and inflammation are described. Also described are agents such as antibodies which can modulate LERK-2-mediated cell adhesion, as well as methods of treating angiogenic diseases and inflammatory diseases.
Claims8
A method of inhibiting LERK-2-mediated cell adhesion, comprising the step of contacting a cell expressing LERK-2 with an antibody produced by the hybridoma having American Type Culture Collection Accession No. HB-12412.
A method of inhibiting LERK-2-mediated cell adhesion, comprising the step of contacting a cell expressing LERK-2 with an antigen-binding fragment of an antibody produced by the hybridoma having American Type Culture Collection Accession No. HB-12412.
A method of inhibiting LERK-2-mediated cell adhesion, comprising the step of contacting a cell expressing LERK-2 with an antibody produced by the hybridoma having American Type Culture Collection Accession No. HB-12413.
A method of inhibiting LERK-2-mediated cell adhesion, comprising the step of contacting a cell expressing LERK-2 with an antigen-binding fragment of an antibody produced by the hybridoma having American Type Culture Collection Accession No. HB-12413.
Dependencies are inferred from the claim text.